<- Go Home
Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Market Cap
$2.5M
Volume
271.8K
Cash and Equivalents
$1.0M
EBITDA
-$7.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$413.0K
Profit Margin
91.37%
52 Week High
$8.92
52 Week Low
$2.23
Dividend
N/A
Price / Book Value
0.25
Price / Earnings
0.37
Price / Tangible Book Value
0.25
Enterprise Value
$2.7M
Enterprise Value / EBITDA
-0.39
Operating Income
-$8.2M
Return on Equity
128.46%
Return on Assets
-33.22
Cash and Short Term Investments
$1.0M
Debt
$1.2M
Equity
$10.0M
Revenue
$452.0K
Unlevered FCF
-$3.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium